Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52
   PubMed Web of Science ®Google Scholar
• Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;11:133-46
   Google Scholar
• Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragón, Spain. J Neurol Sci 2003;216:89-93
   PubMed Web of Science ®Google Scholar
• Aladro Y, Alemany MJ, Pérez-Vieitez MC, et al. Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 2005;24:70-5
   PubMed Web of Science ®Google Scholar
• Ares B, Prieto JM, Lema M, et al. Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult Scler 2007;13:262-4
   PubMedGoogle Scholar
• García Merino A, Fernández O, Montalbán X, et al. [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy]. Neurologia 2010;25:378-90
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ: HEPAC: Health Econ Prev Care 2006;7:S65-S74
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
   PubMed Web of Science ®Google Scholar
• Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. ¿Cuánto cuesta un brote de esclerosis múltiple en Cataluña. Neurologia 2006;21:341-7
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008;14:679-90
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy 2009;7:91-108
   PubMedGoogle Scholar
• Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications. Pharmacoeconomics 2009;27:39-53
   PubMed Web of Science ®Google Scholar
• Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther 2010;32:717-28
   PubMed Web of Science ®Google Scholar
• Janković SM, Kostić M, Radosavljević M, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition. Vojnosanit Pregl 2009;66:556-62
   PubMed Web of Science ®Google Scholar
• Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011 26;77:355-63
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-68
   PubMed Web of Science ®Google Scholar
• Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in northeast Scotland. J Neurol Neurosurg Psychiatry 1987;50:523-31
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística. Revisión del Padrón municipal 2010. Datos a nivel nacional. INE 2011. http://www.ine.es/jaxi/tabla.do. Accessed at 7/2/2011
   Google Scholar
• Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in Germany. Stockholm School of Economics Working Paper Series in Economics and Finance. Final Version - August 12, 2000
   Google Scholar
• Ford CC, Johnson KP, Lisak RP, et al. Copaxone Study Group. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluación del Servicio Canario de la Salud; 2008. Informes de Evaluación de Tecnologías Sanitarias: SESCS N° 2006/22. http://aunets.isciii.es/ficherosproductos/132/MemoriaFinal.pdf. Accessed at 18/10/2010
   Google Scholar
• Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-61
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-12
   PubMedGoogle Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística. Defunciones según la Causa de Muerte 2008. Resultados nacionales. INE 2010. http://www.ine.es/jaxi/tabla.do?path=/t15/p417/a2008/l0/&file=01001.px&type=pcaxis&L=0. Accessed at 7/2/2011
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8
   PubMed Web of Science ®Google Scholar
• Clanet M, Kappos L, Hartung HP, et al. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004;10:139-44
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a subcutaneously in Multiple Sclerosis) Study Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-36
   Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
   PubMed Web of Science ®Google Scholar
• Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 2009;277:S29-32
   PubMedGoogle Scholar
• EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208
   Google Scholar
• Badia X, Roset M, Monserrat S, et al. La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc) 1999;112(1Suppl):79-85
   Google Scholar
• Badía X, Montserrat S, Roset M, et al. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res 1999;8:303-10
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística. Índice de precios al consumo 2009. Base 2006. Resultados nacionales INE 2010. http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t25/p138&file=inebase&L=0. Accessed at 7/2/2011
   Google Scholar
• European Medicines Agency (EMEA). European public assessment report (EPAR) for Avonex. Summary of product Characteristics (last updated 22/09/2011). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf. Accessed 30/12/2011
   Google Scholar
• European Medicines Agency (EMEA). European public assessment report (EPAR) for Betaferon. Summary of product Characteristics (last updated 18/10/2011). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf. Accessed 30/12/2011
   Google Scholar
• European Medicines Agency (EMEA). European public assessment report (EPAR) for Extavia. Summary of product Characteristics (last updated 22/06/2011). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000933/WC500034701.pdf. Accessed 30/12/2011
   Google Scholar
• European Medicines Agency (EMEA). European public assessment report (EPAR) for Rebif. Summary of product Characteristics (last updated 22/06/2011). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000933/WC500034701.pdf. Accessed 30/12/2011
   Google Scholar
• Ministerio de Sanidad y Política Social. Agencia Española de medicamentos y productos sanitarios. ficha técnica Copaxone. Summary of product Characteristics (last updated September 2009). Available at: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=65983&formato=pdf&formulario=FICHAS&file=ficha.pdf. Accessed 30/12/2011
   Google Scholar
• Consejo General de Colegios de Farmacéuticos. Catálogo de especialidades farmacéuticas. Consejo Plus 2009. Madrid: Consejo General de Colegios de Farmacéuticos; 2007. http://www.portalfarma.com. Accessed at 7/2/2011
   Google Scholar
• Instituto Nacional de Estadística. Condiciones de trabajo y relaciones laborales Salario mínimo interprofesional. Serie 1990–2010. INE 2011. http://www.ine.es/jaxi/tabla.do?type=pcaxis&path=/t22/a063/a1998/l0/&file=m30026.px. Accessed at 7/2/2011
   Google Scholar
• Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work 2006;27:143-51
   PubMedGoogle Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac San 2002;16:334-43
   PubMedGoogle Scholar
• Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm 2004;10(Suppl):S12-19. http://www.amcp.org/data/jmcp/June04Supplement1.pdf. Accessed March 5, 2007
   Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
   Google Scholar
• Rubio-Terrés C, Arístegui Ruiz I, Medina Redondo F, et al. Análisis coste-utilidad del tratamiento de la esclerosis multiple remitente-recidivante con acetate de glatiramero o interferón beta en España. Farm Hosp 2003;27:159-65
   PubMedGoogle Scholar
• Garrison LP, Jr., Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 2007;10:326-35
   PubMed Web of Science ®Google Scholar
• Goeree R, Burke N, O’Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23:671-82
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin D, Francis G, et al; EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained at 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74
   Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar